University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > HIV Meds Updates
HIV Meds Updates
Related Resources
ARV Profiles
ARV Charts & Tables
Drug Interactions
Latest Updates
Efavirenz and Bone Mineral Density, posted August 1, 2014.
Efavirenz and Suicidality, posted August 1, 2014.
Drug Interactions: Integrase Inhibitors and Cations, posted August 1, 2014.
Fast Takes, ATV pediatric powder formulation; Rilpivirine and rifabutin; posted August 1, 2014.
Archive
Darunavir + Raltegravir without NRTIs: NEAT Study Results, posted April 25, 2014.
First-Line Therapy: Raltegravir, Darunavir, or Atazanavir?, posted April 22, 2014.
Polypharmacy in HIV-Infected Individuals, posted December 18, 2013.
Clinically Significant Drug Interactions with Dolutegravir, posted November 12, 2013.
Dolutegravir vs Darunavir/Ritonavir: Open-Label Study in ARV-Naive Patients, posted October 24, 2013.
Cobicistat and Stribild Use in Patients with Renal Insufficiency, posted October 15, 2013.
Dolutegravir Receives FDA Approval, posted October 7, 2013.
Updated Opportunistic Infections Guidelines, posted October 7, 2013.
Updated Occupational PEP Guidelines, posted October 7, 2013.
Updates to the Database of ARV Drug Interactions, reference table.
Fast Takes, Darunavir once-daily dosing for children. May 1, 2013.
Comparison of 2 Tenofovir Prodrugs: TAF (GS 7340) and TDF, research brief. May 1, 2013.
Dolutegravir More Effective Than Raltegravir in Treatment-Experienced Patients, research brief. May 1, 2013.
Interactions with Hepatitis C Protease Inhibitors, interactions studies. May 1, 2013.
Updates to the Database of ARV Drug Interactions, reference table. November 2012-April 2013.
Fast Takes, The "quad" pill, ARV generics, Truvada/PrEP approval. October 5, 2012.
Pitavastatin and Darunavir/Ritonavir, research brief. October 5, 2012.
Dolutegravir in Initial Therapy: Two Phase 3 Studies, research brief. October 5, 2012.
Cobicistat as a PK Booster of Atazanavir, research brief. October 5, 2012.
Elvitegravir as Effective as Raltegravir in Treatment-Experienced Patients, research brief. October 5, 2012.
Updates to the Database of ARV Drug Interactions, reference table. May-October, 2012.
More on Protease Inhibitors and Corticosteroids, research brief. May 18, 2012.
More on Interactions between Darunavir and Pravastatin: To Use or Not to Use?, research brief. May 18, 2012.
Fast Takes, Fosamprenavir, etravirine. May 17, 2012.
ARV Interactions with HCV Protease Inhibitors, reference table and overview. April 30, 2012.
Updates to the Database of ARV Drug Interactions, reference table. January-April, 2012.
Winter 2011-12
Research Briefs: Once-Daily Etravirine; Switching from Efavirenz to Rilpivirine; Darunavir + Raltegravir without NRTIs, Revisited
Fast Takes: Rilpivirine Added to DHHS Recommendations; Raltegravir-Associated Skin Reactions; Darunavir Oral Suspension
Summer 2011
Interactions: Buprenorphine/Naloxone with Raltegravir; Pitavastatin with Lopinavir/Ritonavir; Sustained Effect of Efavirenz on Rilpivirine Serum Concentrations; Hepatitis C NS3 Protease Inhibitors and Antiretroviral Drugs
Research Briefs: Preexposure Prophylaxis with Oral Tenofovir or Tenofovir/Emtricitabine; Dolutegravir in Treatment-Naive Patients; Lersivirine: A New NNRTI
Fast Takes: Rilpivirine approved; 1-pill, once-daily combination regimen: rilpivirine/tenofovir/emtricitabine; Etravirine 200 mg tablet approved; HCV drug approvals
Reference Table: Updates to the Database of ARV Drug Interactions
Winter/Spring 2011
Research Briefs: Darunavir + Raltegravir without NRTIs; Raltegravir: Inferior Results with Once-Daily Dosing; Hepatitis C Infection and Telaprevir; Rilviripine Redux
Fast Takes: Darunavir dosage in treatment-experienced patients
Reference Table: Updates to the Database of ARV Drug Interactions
Spring/Summer 2010
Interactions: Rosuvastatin Levels Increased by Ritonavir-Boosted Darunavir; Fosamprenavir and Posaconazole
Research Briefs: Recent Advances in Once-Daily Therapies and Fixed-Dose Combination Regimens: Rilpivirine (TMC278) in Initial Therapy; S/GSK 572 in Initial Therapy: Interim Results of SPRING-1; Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir ("Quad" Pill) in Initial Therapy; Novel Pharmacokinetic Booster Cobicistat (GS-9350)
Fast Takes: Maraviroc in patients with kidney disease; Didanosine and noncirrhotic portal hypertension
Reference Table: Updates to the Database of ARV Drug Interactions
Winter 2010
Interactions: Efavirenz and Levonorgestrel; Lopinavir/ritonavir and Buprenorphine
Research Briefs: Vicriviroc in Treatment-Experienced Patients
Fast Takes: Ritonavir tablet formulation; Maraviroc approved for initial therapy; Saquinavir/ritonavir and possible risk of abnormal heart rhythms
Reference Table: Updates to the Database of ARV Drug Interactions
Fall 2009
Research Briefs: Kaletra Dosage Adjustment for Patients on Efavirenz or Nevirapine; Once-Daily Raltegravir; Atazanavir and Lopinavir/Ritonavir in Hemodialysis
Reference Table: Updates to the Database of ARV Drug Interactions
Summer 2009
Research Briefs: Regimen Simplification: Atazanavir vs Atazanavir/Ritonavir; Atazanavir/Ritonavir in Pregnancy; Investigational Integrase Inhibitor Shows Potent Activity in Early Studies
Reference Table: Updates to the Database of ARV Drug Interactions
Fast Takes: Raltegravir approved for initial therapy
Spring 2009
Research Briefs: Rosiglitazone and Heart Disease; Antipsychotics and Sudden Cardiac Death; New Pharmacokinetic Booster on the Horizon; Interleukin-2: No Clinical Benefit; Raltegravir Substitution for Lopinavir/Ritonavir (SWITCHMRK Study); Abacavir and Myocardial Infarction Risk: Additional Data
Reference Table: Updates to the Database of ARV Drug Interactions
Fast Takes: Darunavir: Traditional approval
Guidelines: New Guidelines: Adult OI prevention and treatment; Updated: Pediatric ARV guidelines; Updated: Perinatal guidelines
Winter 2009
Research Briefs: Darunavir Approved for Use with Boosted Ritonavir as "Preferred" PI, Pediatric Dosing
Fast Takes: Recent news about maraviroc, abacavir: pediatric formulation, and abacavir/lamivudine: DHHS recommendations
Fall 2008
Research Briefs: Pregabalin for Neuropathic Pain: Not More Effective Than Placebo; Abacavir/Lamivudine: Higher Rates of Virologic Failure in ARV-Naive Patients with HIV RNA ≥100,000 copies/mL compared with Tenofovir/Emtricitabine; Abacavir and Risk of Myocardial Infarction: The SMART Study
Interactions: Atazanavir: Interactions with Efavirenz, Nevirapine, and Oral Hormonal Contraceptives
Fast Takes: Recent news about ritonavir, darunavir, atazanavir + ritonavir, tenofovir, zidovudine, and didanosine
Summer 2008
Research Briefs: Abacavir and Didanosine Associated with Increased Risk of Myocardial Infarction; Testing for Chemokine Coreceptor Tropism
Interactions: Rosuvastatin with Lopinavir/Ritonavir and Tipranavir; Rifampin and "Super-Boosted" Protease Inhibitors
Fast Takes: Recent news about nelfinavir, tipranavir, lopinavir/ritonavir, and nevirapine
Spring 2008
Research Briefs: Atazanavir Efficacy Data and Changes in Dosage Recommendations; Raltegravir Substitution for Enfuvirtide; HLA-B*5701 Screening
Reference Table: Etravirine-ARV Interactions
Fast Takes: Recent news about darunavir, lamivudine, lopinavir/ritonavir and amprenavir